Brief Article
Copyright ©2013 Baishideng Publishing Group Co.
World J Gastroenterol. Aug 28, 2013; 19(32): 5278-5285
Published online Aug 28, 2013. doi: 10.3748/wjg.v19.i32.5278
Table 1 Patients’ baseline characteristics (mean ± SE)
CharacteristicPatients (n = 46)
Sex (M/F)30/16
Age (yr)57.9 ± 1.28
Time from OLT (mo)26.3 ± 5.1
ALT (IU/L)152.3 ± 17.8
AST (IU/L)105.9 ± 11.5
Gamma-GT (IU/L)188.7 ± 39.3
Alkaline phosphatases (IU/L)364.7 ± 39.9
Bilirubin (mg/L)1.7 ± 0.37
Viral load (log10)6.25 ± 0.09
Genotypes 1/4 vs 2/336/10
F1/F2/F3/F413/16/9/8
Fibrosing cholestatic hepatitis3
Cyclosporine A vs tacrolimus7/39
Table 2 Variables associated with sustained virological response according to univariate analysis
Variabler95%CIP-value
BMI > 25 kg/m20.300.01455-0.5458  0.0400
Genotypes 2-3 vs 1-40.370.09103-0.5974  0.0100
RVR0.540.2992-0.71940.0001
HCV-RNA clearance during treatment0.820.6948-0.89670.0001
CyA vs FK immunosuppression0.410.09597-0.6519  0.0120
Table 3 Histological response after treatment (mean ± SE)
Grading
Staging
BeforeAfterP-valueBeforeAfterP-value
Sustained virological response (n = 9)7.2 ± 0.82.6 ± 0.60.00392.1 ± 0.31.0 ± 0.10.0031
Long-term treated (n = 19)7.9 ± 0.74.7 ± 0.60.00012.7 ± 0.32.5 ± 0.30.0001
Drop out (n = 7)7.4 ± 1.16.0 ± 0.8NS2.6 ± 0.63.0 ± 0.6NS